Mervi Putkonen

Turku, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Evolution of treatment practices and outcomes in multiple myeloma during 2013-2022: a Finnish real world registry study.

Evolution of treatment practices and outcomes in multiple myeloma during 2013-2022: a Finnish real world registry study.

Journal: Acta oncologica (Stockholm, Sweden)
Published: December 04, 2024

A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.

A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.

Journal: Annals of hematology
Published: September 20, 2024

Correction to: Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.

Correction to: Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.

Journal: Annals of hematology
Published: September 13, 2024

Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.

Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.

Journal: Annals of hematology
Published: February 27, 2024

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Journal: Cancers
Published: January 27, 2024

Recent trends in incidence, survival and treatment of multiple myeloma in Finland - a nationwide cohort study.

Recent trends in incidence, survival and treatment of multiple myeloma in Finland - a nationwide cohort study.

Journal: Annals of hematology
Published: September 06, 2023

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.

Journal: The Journal of clinical investigation
Published: July 14, 2022

Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.

Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.

Journal: Journal of clinical apheresis
Published: July 08, 2022

Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.

Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.

Journal: Transfusion
Published: December 07, 2020

CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study.

CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study.

Journal: Transfusion
Published: January 03, 2020

Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD.

Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD.

Journal: Frontiers in immunology
Published: November 11, 2019

Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease After Allogeneic HSCT.

Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease After Allogeneic HSCT.

Journal: Frontiers in immunology
Published: March 20, 2019
Showing 1-12 of 34

Last Updated: 09/26/2026